Ravi Akella, MD
Internal Medicine · Orlando, FLNPI 1568405272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,325 of the $4,819 with a category attached, or 69.0%. AbbVie accounts for 91.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $4,525 and has fallen 98.8% since, to $56 in 2024. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $229.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Gilead$87
- Ironwood Pharmaceuticals, Inc$85
- Ambu Inc.$56
- Abbott$49
- Novo Nordisk$45
- plus $81 from 3 others
What the payments were for
- Speaking & faculty fees$3,32569%
- Travel & lodging$74916%
- Food & beverage$74515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $4,417 |
| Gilead | 1 | $87 |
| Ironwood Pharmaceuticals, Inc | 1 | $85 |
| Ambu Inc. | 1 | $56 |
| Abbott | 2 | $49 |
| Novo Nordisk | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Pfizer | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$4,221
How this compares
$4,819 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $863 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $804 |
| Fluticasone Propionate | 13 | $109 |
| Amlodipine Besylate | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Orlando
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.